Porton Advanced has been offering comprehensive CRO and CDMO support to over 100 clients across the globe for their gene and cell therapy endeavors. These biotech startups harbor strong convictions regarding the substantial potential of their drug products and technologies within the dynamic pharmaceutical landscape. Some are even open to licensing out these assets to international innovators. Our ability to engage with these companies at their early stages fills us with excitement as we endeavor to facilitate connections between these innovators and showcase our clients' assets across various markets.
We have basic information for all the pipelines listed above, including modalities, targets, indications, safety and efficacy data, and clinical data. Should you be interested, please get in touch with us and ask for more details.
| Pipeline | Therapies | Target | Indication | Stage |
| PAS-001 | CAR-T | NKG2DL | Glioblastoma, Colorectal Cancer, Hepatocellular Carcinoma |
IND approval in China |
| PAS-002 | CAR-T | NKG2DL, CLDN18.2 | Pancreatic Cancer, Gastric Cancer |
Investigator-initiated clinical trials* (Pre-IND) in China |
| PAS-003 | CAR-T | NKG2DL, CD33 | Acute Myeloid Leukemia |
Preclinical research in China |
| PAS-009 | CAR-T | Mesothelin | Recurrent Ovarian Carcinoma |
IND approval in China |
| PAS-010 | CAR-T | Mesothelin | Advanced Ovarian Carcinoma |
IND approval in China |
| PAS-011 | CAR-T | CD19 | (R/R) B-ALL |
NDA approved (NMPA) |
*Investigator-initiated clinical trials (IIT) in China are conducted before IND application and support drug development.
